ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank46
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P46
Within normal range
vs 2Y Ago
-0.8x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -31.07% |
| Q3 2025 | -41.89% |
| Q2 2025 | 116.66% |
| Q1 2025 | 120.62% |
| Q4 2024 | 27.14% |
| Q3 2024 | -28.37% |
| Q2 2024 | -4.68% |
| Q1 2024 | -59.17% |
| Q4 2023 | 39.08% |
| Q3 2023 | 55.96% |
| Q2 2023 | -3.72% |
| Q1 2023 | 586.91% |
| Q4 2022 | -221.45% |
| Q3 2022 | 131.55% |
| Q2 2022 | 39.37% |
| Q1 2022 | -55.45% |
| Q4 2021 | -125.56% |
| Q3 2021 | -2341.49% |
| Q2 2021 | -98.83% |
| Q1 2021 | 462.02% |
| Q4 2020 | -253.72% |
| Q3 2020 | -107.73% |
| Q2 2020 | 1121.05% |
| Q1 2020 | -64.40% |
| Q4 2019 | -77.96% |
| Q3 2019 | 359.38% |
| Q2 2019 | -66.80% |
| Q1 2019 | -47.52% |
| Q4 2018 | 227.35% |
| Q3 2018 | -3.19% |
| Q2 2018 | -62.53% |
| Q1 2018 | 45.08% |
| Q4 2017 | -7.49% |
| Q3 2017 | 1708300.00% |
| Q2 2017 | -99.98% |
| Q1 2017 | -45.96% |
| Q4 2016 | 1014.58% |
| Q3 2016 | -67.52% |
| Q2 2016 | -69.58% |
| Q1 2016 | 133.28% |